Events |

Drug for Neglected Diseases Working Group Meeting, Rio de Janeiro, Brazil, December 2-3, 2002, Meeting Agenda

Drug for Neglected Diseases Working Group Meeting
Rio de Janeiro, Brazil, 2-3, December 2002

Monday 2 December 2002

08:30 - 09:00 Registration

09:00 - 10:00 1st Plenary Session
Welcome, introduction and update

Chair: Dr James Orbinski, Médecins sans Frontières (MSF), Campaign for Access to Essential Medicines, Canada

Welcome and Introduction
Dr Paulo Buss, President Fiocruz, Brazil

Overview of the achievements of the Access Campaign and DND Working Group over the last three years, and future challenges.
Dr Bernard Pécoul, Director of the MSF Campaign for Access to Essential Medicines, Switzerland

Update on the DNDi
Dr Yves Champey, Director DNDi feasibility study, France

10:00 - 11:00 2nd Plenary Session
Who's driving the R&D agenda?

Chair: Dr Ayoade Oduola, Programme for Research and Training in Tropical Diseases (TDR), Switzerland

How to translate scientific progress into health tools that meet the needs of poor people
Dr Carlos Morel, Director, WHO - Programme for Research and Training in Tropical Diseases (TDR), Switzerland

Does pharmaceutical innovation address priority health needs? Are we getting our money's worth?
Dr Graham Dukes, University of Oslo, Norway

11:00-11:30 Coffee Break

11:30-13:00 2nd Plenary Session

Can public, academic and other non-profit researchers be mobilized to do more needs-driven research? If so, how?
Dr Motlalepula Gilbert Matsabisa, Medical Research Council, South Africa

Dr Vasantha Muthuswamy, Indian Council of Medical Research, India
Dr Pierre Druilhe, Institut Pasteur, France

13:00 -14:30 Lunch

14:30 -16:00 3rd Plenary Session
Regulatory Barriers to R&D for Neglected Diseases?

Chair: Prof Kris Weerasuryia, Sri Lanka

Weighing benefits and risks in medical research for neglected diseases
Prof Solomon Benatar, Bioethics Centre, University of Cape Town, South Africa

Does global harmonisation of regulatory requirements constrain the evaluation and availability of new drugs for neglected diseases?
Prof Patrice Trouiller, University of Grenoble, France

Defining essential regulatory issues for R&D for neglected diseases
Dr Gonzalo Vecina Neto, Director of ANVISA ( National Agency for Health Vigilance), Brazil


End of Day One

16:00-16:30 Transportation to the Theatre de la Maison de France

Tuesday December 3, 2002

08:30-10:30 4th Plenary Session
Research capacity, production capacity and technology transfer

Chair: Dr Eloan dos Santos Pinheiro, Far-Manguinhos, Brazil
Co-chair: Michel Lotrowska, MSF, Campaign for Access to Essential Medicines, Brazil

Technology transfer and the TRIPS Agreement: what are the obligations of the industrialized world, and what is actually happening?
Prof Fred Abbott, Florida State University College of Law, USA

Research Capacity in Africa: more than a place to do clinical trials.
Dr Monique Wasunna, Kenya Medical Research Institute, Kenya

Why is innovation in the public sector necessary? Is it feasible?
Case of fixed-dose combination ARVs.
Dr Krisana Kraisintu, Government Pharmaceutical Organization (GPO), Thailand

Pharmaceutical Technology transfer to Africa: a key to sustainable solutions
Dr Giorgio Roscigno, Global Alliance for Tuberculosis Drug Development, Belgium


10:30 11:00 Coffee Break

11:00-13:00 Simultaneous Breakout Sessions

1. Knowledge management and intellectual property strategies for not-for-profit drug development
- Chair: Dr Motlalepula Gilbert Matsabisa, Medical Research Council, South Africa
- Introduction: Dr Sibongile Pefile, Centre for the Management of Intellectual Property in Health Research & Development (MIHR), USA

2. R&D for Neglected Diseases: Incentives and policy changes to mobilize public and academic sector scientists and their institutions (North/South)
- Chair: Dr Fernando de Nielander Ribeiro, Director of FINEP, Brazil
- Introduction: Dr Simon Croft, London School of Hygiene and Tropical Medicine, UK
Discussant: Dr Jean Claude Dujardin, Institute for Tropical Medicine, Belgium

3. The Cases of W 135 meningitis vaccine, and the rotavirus vaccine: Strategies to encourage health needs-driven R&D.
- Chair: Dr Akira Homma, BioManguinhos, Brazil
- Introduction: Dr Philippe Guérin, Norwegian Institute of Public Health, Norway

4. What are the issues and implications of increased spending on biowarfare for R&D for Neglected Diseases?
- Chair: Dr Robert Ridley, WHO - Programme for Research and Training in Tropical Diseases (TDR), Switzerland
- Introduction: Background document prepared by Prof David Fidler, Indiana University Law School, USA, introduction by Ellen 't Hoen, MSF, Campaign for Access to Essential Medicines, France

13:00-14:30 Lunch

14:30-15:30 Reports of the breakout sessions
Chair: Prof. Dyann Wirth, Director, Harvard School of Public Health, USA

15:30-16:30 5th Plenary Session

Changing the global rules: how to create a system to address development of and assess to effective tools to combat neglected diseases?
Chair: Sakiko Fukuda-Parr, United Nations Development Programme (UNDP), USA
Co-Chair: Dr Jorge Bermudez, Oswaldo Cruz Foundation, Brazil

Public sector R&D: is it a different paradigm?
Dr Yongyuth Yuthavong, Institute of Sciences and Technologies, Thailand

Are Public Private Partnerships the Answer? Lessons from GAVI.
Mary Starling, London School of Hygiene & Tropical Medicine, UK

16:15 - 16:45 Coffee Break

16:45 - 18:00 5th Plenary Session (continuation)

Is there a role for IP in stimulating needs-driven R&D in developing countries? Recommendations from the UK Commission on IPR.
Charles Clift, Commission on Intellectual Property Rights, UK

What alternative frameworks could be developed to finance R&D that would address real health needs?
James Love, Consumer Project on Technology, USA

18:00-18:30 Reinventing the working group: promoting the development of innovative strategies and medical solutions to address the health needs of neglected patients.

Chair: Dr Els Torreele, MSF, Campaign for Access to Essential Medicines, Belgium

18:30 Closure of the meeting
Dr. James Orbinski, Médecins Sans Frontières (MSF), Campaign for Access to Essential Medicine, Canada